Harry Sokol : member of the Science and Ethic Committee

/static/themes-v3/default/images/default/about/intro.jpg?1516194360

Harry Sokol

Gastroenterologist and Hepatologist

Practicing at the Gastroenterology and Nutrition Department at the Hopital Saint-Antoine in Paris, Professor Sokol specializes in the role microbiota plays in immunity. He is overseeing the first fecal transplant clinical trials in France in patients with Crohn's disease. In 2016, he was the recipient of a "Starling Grant" from the European Research Council, for the quality of his work. More than just a fundamental research project, Professor SOKOL has the ambition of developping treatments that will allow doctors to repair microbiotic deteriorations in patients living with inflammatory intestinal diseases, perhaps even halting the development of the disease by acting on it early and in a precise manner.

Full disclosure: Professor Harry Sokol works or has worked with companies in the health care sector. More information at: https://www.transparence.sante.gouv.fr/.

Created: 1/27/20 - Updated: 1/27/20


See scientific publications

Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease.

Gut microbiota in PSC : From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., Nature Microbiology, J

Fecal Microbiota Transplantation for Ulcerative Colitis.